Immune Biomarkers May Predict Bladder Cancer Therapy Response

Researchers at Northwestern Medicine have identified immune system markers that may help predict who responds to BCG bladder cancer therapy and who does not, according to findings published in the Journal of Clinical Investigation. The discovery could lead to more personalized treatment approaches for patients with bladder cancer, a disease that affects hundreds of thousands of people annually.

BCG (Bacillus Calmette-Guérin) therapy is a standard immunotherapy for non-muscle invasive bladder cancer, but its effectiveness varies widely among patients. Currently, there is no reliable way to determine which patients will benefit from the treatment. The Northwestern team analyzed tumor samples from patients and identified specific biomarkers in the immune microenvironment that correlate with treatment outcomes. These biomarkers could enable clinicians to tailor therapy, sparing non-responders from ineffective treatments and potential side effects.

The study underscores the growing role of immunotherapy in oncology. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also working to refine immunotherapy approaches, as noted in the press release. However, the Northwestern research focuses specifically on predictive biomarkers, which could complement therapeutic innovations.

Bladder cancer is the sixth most common cancer in the United States, with an estimated 83,000 new cases diagnosed each year. BCG therapy has been a mainstay for early-stage bladder cancer for decades, but up to 40% of patients do not respond. Identifying biomarkers early could help guide treatment decisions, potentially improving outcomes and reducing healthcare costs.

The researchers used advanced genomic and proteomic techniques to profile immune cells in tumors from patients who received BCG therapy. They found that higher levels of certain immune cell types, such as CD8+ T cells and natural killer cells, were associated with better responses. Conversely, a predominance of immunosuppressive cells like regulatory T cells correlated with treatment failure. These findings suggest that the balance of immune cells in the tumor microenvironment is critical for BCG efficacy.

Further validation in larger clinical trials is needed before these biomarkers can be used routinely. If confirmed, they could be incorporated into diagnostic tests to guide therapy. The study also highlights the potential of combining BCG with other immunotherapies to boost response rates in patients with unfavorable biomarker profiles.

The complete study is available in the Journal of Clinical Investigation. For more information on immunotherapy advancements, you can visit Calidi Biotherapeutics. This research represents a step toward precision medicine in bladder cancer, where treatment is tailored to the individual's immune landscape.